Integrated NY-ESO-1 antibody and CD8(+) T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab

Ipilimumab, a monoclonal antibody against cytotoxic T lymphocyte antigen 4 (CTLA-4), has been shown to improve survival in patients with advanced metastatic melanoma. It also enhances immunity to NY-ESO-1, a cancer/testis antigen expressed in a subset of patients with melanoma. To characterize the a...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Yuan, Jianda, Adamow, Matthew, Ginsberg, Brian A., Rasalan, Teresa S., Ritter, Erika, Gallardo, Humilidad F., Xu, Yinyan, Pogoriler, Evelina, Terzulli, Stephanie L., Kuk, Deborah, Panageas, Katherine S., Ritter, Gerd, Sznol, Mario, Halaban, Ruth, Jungbluth, Achim A., Allison, James P., Old, Lloyd J., Wolchok, Jedd D., Gnjatic, Sacha
Format: Artigo
Langue:Inglês
Publié: National Academy of Sciences 2011
Sujets:
Biological Sciences
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC3189057/
https://ncbi.nlm.nih.gov/pubmed/21933959
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1073/pnas.1110814108
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires